TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
November 07 2022 - 8:01AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from solid tumors, today announced the poster
presentation of new preclinical data at the Society for
Immunotherapy of Cancer (SITC) Conference 37th Annual Meeting,
taking place November 8-12, 2022. The poster entitled “The
Functional Activity of gavo-cel TRuC-T Cells is Not Impaired by
Soluble Mesothelin” highlights preclinical data evaluating the
impact of soluble mesothelin at high, supraphysiological levels on
the functional activity of the Company’s proprietary autologous and
allogeneic mesothelin-directed T Cell Receptor Fusion Construct
(TRuC®) T cells.
Mesothelin (MSLN), a protein which plays an
active role in both malignant transformation and tumor
aggressiveness, undergoes shedding in the tumor microenvironment,
generating soluble mesothelin (sMSLN). These sMSLN levels are
associated with tumor burden in malignant pleural/peritoneal
mesothelioma (MPM). High, circulating levels of sMSLN have been
implicated as a potential obstacle to maximizing the activity of
anti-mesothelin therapies. To address the potential impact of sMSLN
on the function of gavo-cel, acute and chronic in vitro challenge
studies were performed in the presence of supraphysiological sMSLN
levels. Levels of sMSLN 50-fold higher than were measured in MPM
patients had no observed impact on the functional activity of
gavo-cel T cells with respect to tumor cell killing and cytokine
production. These results suggest that the levels of sMSLN present
in the circulation of MPM patients likely do not pose a concern for
the clinical activity of gavo-cel.
Poster Details:
Poster Title: The Functional
Activity of gavo-cel TRuC-T Cells is Not Impaired by Soluble
MesothelinAbstract Number: 219Date &
Time: Monday, November 7, 2022; 11:40am ET
The poster presented at SITC is available in the
Presentations section of the Investors page of the Company’s
website at investors.tcr2.com.
About
TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from solid
tumors. The Company is focused on the discovery and
development of product candidates against novel and complex targets
utilizing its proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells). The TRuC platform is
designed to specifically recognize and kill cancer cells by
harnessing signaling from the entire TCR, independent of human
leukocyte antigens (HLA). For more information about TCR2, please
visit www.tcr2.com.
Forward-looking
Statements
This press release contains forward-looking
statements and information within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as "may," "will," "could",
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "seeks," "endeavor,"
"potential," "continue" or the negative of such words or other
similar expressions can be used to identify forward-looking
statements. These forward-looking statements include, but are not
limited to, express or implied statements regarding the therapeutic
potential of gavo-cel, the development of TCR2‘s TRuC-T cells,
their potential characteristics, applications and clinical utility,
and the potential therapeutic applications of the Company’s TRuC-T
cell platform.
The expressed or implied forward-looking
statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions,
including, without limitation: uncertainties inherent in clinical
studies and in the availability and timing of data from ongoing
clinical studies; whether interim results from a clinical trial
will be predictive of the final results of the trial; whether
results from preclinical studies or earlier clinical studies will
be predictive of the results of future trials; the expected timing
of submissions for regulatory approval or review by governmental
authorities, including review under accelerated approval processes;
orphan drug designation eligibility; regulatory approvals to
conduct trials or to market products; TCR2’s ability to maintain
sufficient manufacturing capabilities to support its research,
development and commercialization efforts, including TCR2’s ability
to secure additional manufacturing facilities; whether TCR2's cash
resources will be sufficient to fund TCR2's foreseeable and
unforeseeable operating expenses and capital expenditure
requirements, the impact of the COVID- 19 pandemic on TCR2’s
ongoing operations; and other risks set forth under the caption
"Risk Factors" in TCR2’s most recent Annual Report on Form 10-K,
most recent Quarterly Report on Form 10-Q and its other filings
with the Securities and Exchange Commission. In light of these
risks, uncertainties and assumptions, the forward-looking events
and circumstances discussed in this press release may not occur and
actual results could differ materially and adversely from those
anticipated or implied in the forward-looking statements. You
should not rely upon forward- looking statements as predictions of
future events. Although TCR2 believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur.
Moreover, except as required by law, neither
TCR2 nor any other person assumes responsibility for the accuracy
and completeness of the forward-looking statements included in this
press release. Any forward-looking statement included in this press
release speaks only as of the date on which it was made. TCR2‘
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
Investor and
Media Contact:Carl MauchSenior
Director, Investor Relations and Corporate Communications (617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024